To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Pfizer made one thing clear this week: It's officially back in the obesity race.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...